Ryan G. Casner

Dec 5, 2024 | biorxiv.org | Qian Wang |Yicheng Guo |Ryan G. Casner |Jian Yu

AbstractSARS-CoV-2 has largely evolved to resist antibody pressure, with each successive viral variant becoming more and more resistant to serum antibodies in the population. This evolution has rendered inactive all therapeutic monoclonal antibodies previously authorized, and it is now threatening the remaining clinical product for immunoprophylaxis against COVID-19.

Apr 10, 2023 | biorxiv.org | Lihong Liu |Ryan G. Casner |Yicheng Guo |Qian Wang

Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.